Argent Biopharma Ltd (MGCLF)

[rushmann]

Back in those years, MGC was in it's infant stages with really no revenue producing products. 2017 was a milestone year in that future revenue producing products began coming out, but more importantly, set the stage for a much more robust 2018 and beyond. As you can see from the info provided on this board page, the fruits of the labor from those earlier years will begin paying off this year, and much more so over beyond 2018. MGC is still just warming up for primetime. The next 3-6 months should see deals and products out the door being marketed. Up till now, most have been undergoing quality control measures before release, and before that was R&D which is why I don't really pay attention to the fins 2017 and before. 2018 begins the real fins that need to be looked at. I believe MGC has a fantastic pipeline of products and deals are very close to being finalized. It's still an OTC stock so caution remains, but all signs point to this company doing really well in the near future. I have been in the medical field for 28 years and a medical provider for 17 of those years, and from a medical provider's perspective, I love what I see with MGC.